Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TLL-018 vs Tofacitinib in Rheumatoid Arthritis
NCT06020144Phase 3Completed
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd.
- Start
- Nov 2023
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of girocitinib in rheumatoid arthritis (RA), sponsored by Hangzhou Highlightll Pharmaceutical Co., Ltd.. Started Nov 2023; status: completed.
02
Drugs
girocitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06020144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06020144.